Abstract
Human blood plasma has been the primary source for a number of therapeutic transfusion products for more than forty years now. This situation will continue for quite some time, notwithstanding the arrival in the future of preparations produced by recombinant-DNA technology. Nowadays, a variety of plasma proteins is needed for substitution therapy. These include coagulation factors (among others factors VIII, IX, VII, von Willebrand factor), protease inhibitors (antithrombin III, Cl-esterase inhibitor and, under investigation α1-antitrypsin), immunoglobulins (both normal immunoglobulin and specific immunoglobulins, derived from selected plasma containing high-titer antibodies directed against a specific pathogen) and albumin preparations, the latter being the longest existing plasma product. Other plasma componnents may be needed in the near future like activated factor VII and activated protein C.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Cohn EJ, Strong LE, Hughes WL, et al. Preparation and properties of serum and plasma proteins. IV. A system for the separation into fractions of the protein and lipoprotein components of biological tissues and fluids. J Am Chem Soc 1946; 68: 459–75.
McLellan DS, Knight SR, Aronstam A. The relationship between coagulation factor VIII and ABO blood group status. Med Lab Sci 1988; 45: 131–4.
Andrew M, Carter O, O’Brodovich H, Heigenhauser G. Increases in factor VIII complex and fibrinolytic activity are dependent on exercise intensity. J Appl Physiol 1986; 60: 1917–22.
Nilsson IM, Mikaelsson M, Vilhardt H. The effect of intranasal DDAVP on coagulation and fibrinolytic activity in normal persons. Scand J Haematol 1982; 29: 70–4.
Mannucci PM, Vicente V, Alberca I, et al. Intravenous and subcutaneous administration of Desmopressin (DDAVP) to hemophiliacs: pharmacokinetics and factor VIII responses. Thromb Haemost 1987; 58: 1037–9.
Palmer DS, Harris AS, Tittley P, Rock G. Effectiveness, specificity and safety of intranasal 1-deamino-8-D-arginine vasopressin treatment of normal blood donors. Haemostasis 1988; 18: 187–96.
Mikaelsson M, Nilsson IM, Vilhardt H, Wiechel B. Factor VIII concentrate prepared from blood donors stimulated by intranasal administration of a vasopressin analogue. Transfusion 1982; 22: 229–33.
Weiss HJ. A study of the cation and pH-dependent stability of factors V and VIII in plasma. Thromb Diath Haemorrh 1965; 14: 32–51.
Rock GA, Cruickshank WH, Tackaberry ES, Palmer DS. Improved yields of factor VIII from heparinized plasma. Thromb Res 1979; 36: 294–300.
Smit Sibinga CTh, Welbergen H, Das PC, Griffin B. High-yield method of production of freeze-dried purified factor VIII by blood banks. Lancet 1981;ii:449–50.
Rock GA, Cruickshank WH, Tackaberry ES, Ganz PR, Palmer DS. Stability of VIII:C in plasma: The dependence on protease and calcium. Thromb Res 1983; 29: 521–35.
Morgenthaler JJ, Zuber T, Friedli H. Influence of heparin and calcium chloride on assay, stability and recovery of factor VIII. Vox Sang 1985; 48: 8–17.
Wit HJC de, Scheer G, Muradin J, Does JA van der. Influence of the primary anticoagulant on the recovery of factor VIII in cryoprecipitate. Vox Sang 1986; 51: 172–5.
Krachmalnicoff A, Thomas DP. The stability of factor VIII in heparinized plasma. Thromb Haemost 1983; 49: 224–7.
Mikaelsson ME, Forsman N, Oswaldsson U. Human factor VIII: A calcium-linked protein complex. Blood 1983; 62: 1006–15.
Prowse C, Waterston YG, Dawes J, Farrugia A. Studies on the procurement of blood coagulation factor VIII. In vitro studies on blood components prepared in half-strength citrate anticoagulant. Vox Sang 1987; 52: 257–64.
Rock G, Tittley P, Fuller V. Effect of citrate anticoagulants on factor VIII levels in plasma. Transfusion 1988; 28: 248–52.
Foster PR, Dickson IH, McQuillan TA, et al. Studies on the stability of VIII:C during the manufacture of a factor VIII concentrate for clinical use. Vox Sang 1988; 55: 81–9.
Pflugshaupt R, Kurt G. FPA content–a criterion of quality for plasma as factor VIII source. Vox Sang 1983; 45: 224–32.
Carlebjörk G, Blombäck M, Akerblom O. Improvement of plasma quality as raw material for factor VIII:C concentrates. Storage of whole blood and plasma and interindividual plasma levels of fibrinopeptide A. Vox Sang 1983; 45: 233–42.
Prowse CV, Bessos H, Farrugia A, Smith A, Gabra J. Donation procedure, fibrinopeptide A, and factor VIII. Vox Sang 1984; 46: 55–7.
Törmä E, Myllylä G. Parameters affecting the fractionation of F VIII:C activity in production of very high purity AHF concentrate. Scand J Haematol 1984; 33 (supp1.40): 123–6.
Skjonsberg OH, Kierulf P, Fagerhol MK, Godal HC. Thrombin generation during collection and storage of blood. Vox Sang 1986; 50: 33–7.
Huh YO, Lichtiger B, Giacco GG, Guinee VF, Drewinko B. Effect of donation time on platelet concentrates and fresh-frozen plasma. An in vitro study. Vox Sang 1989; 56: 21–4.
Vermeer C, Soute BAM, Ates G, Brummelhuis HGJ. Contributions to the optimal use of human blood. VII. Increase of the yield of factor VIII in four-donor cryoprecipitate by an improved processing of blood and plasma. Vox Sang 1976; 30: 1–22.
Pietersz RNI, Korte D de, Reesink HW, Dekker WJA, Ende A van den, Loos JA. Storage of whole blood for up to 24 hours at ambient temperature prior to component preparation. Vox Sang 1989; 56: 145–50.
Over J, Pik MPJ, Loos JA, et al. Contributions to the optimization of factor VIII production: Cryoprecipitation and controlled pore glass adsorption. In: Smit Sibinga CTh, Das PC, Seidl S (eds). Plasma fractionation and blood transfusion. Dordrecht: Martinus Nijhoff 1985: 67–78.
Farrugia A, Prowse C. Studies on the procurement of blood coagulation factor VIII: Effects of plasma freezing rate and storage conditions on cryoprecipitate quality. J Clin Pathol 1985; 38: 433–7.
Slichter SJ, Counts RB, Henderson R, Harker LA. Preparation of cryoprecipitated factor VIII concentrates. Transfusion 1976; 16: 616–26.
Report of a Working Party of the Regional Transfusion Directors Committee. Variables involved in cryoprecipitate production and their effect on factor VIII activity. Brit J Haematol 1979; 43: 287–95.
Mason EC. Thaw-siphon technique for production of cryoprecipitate concentrate of factor VIII. Lancet 1978;ii:15–7.
Wensley RT, Snape TJ. Preparation of improved cryoprecipitate factor VIII concentrate. A controlled study of three variables affecting the yield. Vox Sang 1980; 38: 222–8.
Foster PR, Dickson AK, McQuillan TA, Dickson IH, Keddie S, Watt JG. Control of large-scale plasma thawing for recovery of cryoprecipitate factor VIII. Vox Sang 1982; 42: 180–9.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1990 Kluwer Academic Publishers, Boston
About this chapter
Cite this chapter
Over, J., Loos, J.A. (1990). Preservation and Storage of Human Blood Plasma Proteins. In: Smit Sibinga, C.T., Das, P.C., Meryman, H.T. (eds) Cryopreservation and low temperature biology in blood transfusion. Developments in Hematology and Immunology, vol 24. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-1515-5_19
Download citation
DOI: https://doi.org/10.1007/978-1-4613-1515-5_19
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4612-8814-5
Online ISBN: 978-1-4613-1515-5
eBook Packages: Springer Book Archive